Periodic Reporting for period 1 - RASATaC (Regulating RAS Activity to Target RAS-Driven Cancers)

More than a quarter of all cancers exist because of mutations in the RAS family of genes. Considering the pivotal role of these oncogenes, and despite intensive efforts, no effective pan-RAS therapies have successfully made it to the clinic. Notably, these efforts have mainly...